These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34320259)

  • 1. Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS.
    Seyger MMB; Reich A; El Baou C; Schuster C; Riedl E; Paller AS
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e911-e913. PubMed ID: 34320259
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
    Rich P; Goldblum O; Disch D; Lin CY; Merola JF; Elewski B
    J Drugs Dermatol; 2020 Aug; 19(8):741-746. PubMed ID: 32845588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
    Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
    J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Jackson K; Chua L; Velez de Mendizabal N; Pitou C; Rodriguez Capriles C; Paller AS; Lansang P; Seyger MMB; Papp K;
    Br J Clin Pharmacol; 2022 Mar; 88(3):1074-1086. PubMed ID: 34378230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab in nail psoriasis.
    Dattola A; Manfreda V; Mazzilli S; Bianchi L; Giunta A
    Dermatol Ther; 2020 May; 33(3):e13352. PubMed ID: 32232895
    [No Abstract]   [Full Text] [Related]  

  • 7. Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3.
    Egeberg A; Kristensen LE; Vender R; Zaheri S; El Baou C; Gallo G; Riedl E; Schuster C
    Acta Derm Venereol; 2022 Oct; 102():adv00787. PubMed ID: 36121210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis.
    Cather JC; Young CT; Young MS; Cather JC
    Expert Opin Biol Ther; 2021 Aug; 21(8):983-990. PubMed ID: 34106794
    [No Abstract]   [Full Text] [Related]  

  • 9. Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study.
    Youn SW; Kim BR; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e298-e299. PubMed ID: 27976465
    [No Abstract]   [Full Text] [Related]  

  • 10. Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis.
    Huang IH; Wu PC; Yang TH; Li H; Huang YT; Cheng YC; Kuo PH; Lee YH; Huang YC; Tu YK
    J Am Acad Dermatol; 2021 Jul; 85(1):135-143. PubMed ID: 33482253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
    Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis.
    Augustin M; Mrowietz U; Willsmann-Theis D; Gerdes S; Fotiou K; Schuster C; Mert C; Holzkaemper T; Behrens F; Pinter A
    J Dtsch Dermatol Ges; 2024 Feb; 22(2):278-281. PubMed ID: 38185772
    [No Abstract]   [Full Text] [Related]  

  • 13. Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis.
    Merola JF; Ghislain PD; Dauendorffer JN; Potts Bleakman A; Brnabic AJM; Burge R; Riedl E
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1257-1262. PubMed ID: 31919919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
    Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A
    Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
    J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked improvement in nail psoriasis during treatment with adalimumab.
    Irla N; Yawalkar N
    Dermatology; 2009; 219(4):353-6. PubMed ID: 19851059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid response of nail psoriasis to secukinumab in patients with moderate to severe psoriasis after 12 weeks of treatment with a total of 24 weeks of follow-up.
    Go GM; Hong YJ; Lee HJ; Kim M
    Australas J Dermatol; 2024 May; 65(3):e13-e20. PubMed ID: 38288519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
    Jemec GB; Ibler KS
    J Drugs Dermatol; 2012 Aug; 11(8):939-42. PubMed ID: 22859238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.
    Griffiths CEM; Fava M; Miller AH; Russell J; Ball SG; Xu W; Acharya N; Rapaport MH
    Psychother Psychosom; 2017; 86(5):260-267. PubMed ID: 28903122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.